Glaukos Corporation $GKOS Holdings Raised by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System raised its stake in Glaukos Corporation (NYSE:GKOS – Free Report) by 53.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,143 shares of the medical instruments supplier’s stock after acquiring an additional 4,600 shares during the quarter. Maryland State Retirement & Pension System’s holdings in Glaukos were worth $2,158,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of GKOS. Quantinno Capital Management LP grew its stake in shares of Glaukos by 964.0% during the first quarter. Quantinno Capital Management LP now owns 30,836 shares of the medical instruments supplier’s stock valued at $3,320,000 after purchasing an additional 27,938 shares during the last quarter. TimesSquare Capital Management LLC acquired a new stake in shares of Glaukos in the second quarter valued at approximately $20,293,000. BlackRock Inc. acquired a new stake in shares of Glaukos in the second quarter valued at approximately $1,333,318,000. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Glaukos in the second quarter valued at approximately $3,361,000. Finally, Wellington Management Group LLP raised its position in Glaukos by 187.1% in the 2nd quarter. Wellington Management Group LLP now owns 428,215 shares of the medical instruments supplier’s stock worth $59,847,000 after purchasing an additional 279,065 shares during the last quarter. 99.04% of the stock is owned by institutional investors.

Insider Activity at Glaukos

In other news, Director Gilbert Kliman sold 2,500 shares of Glaukos stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $253.00, for a total transaction of $632,500.00. Following the completion of the sale, the director owned 37,406 shares in the company, valued at $9,463,718. The trade was a 6.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.90% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on GKOS. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a research report on Thursday, October 15th. Wall Street Zen upgraded Glaukos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 7th. Mizuho set a $225.00 price objective on Glaukos in a research report on Thursday, October 29th. HC Wainwright lifted their target price on Glaukos from $195.00 to $248.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Finally, UBS Group initiated coverage on Glaukos in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $150.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $216.71.

Read Our Latest Report on Glaukos

Glaukos Trading Down 0.2%

NYSE:GKOS traded down $0.43 on Friday, hitting $245.60. 546,373 shares of the stock were exchanged, compared to its average volume of 1,924,346. The stock has a market capitalization of $14.54 billion, a price-to-earnings ratio of -83.54 and a beta of 0.68. Glaukos Corporation has a 52 week low of $87.32 and a 52 week high of $255.18. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.09 and a current ratio of 4.57. The company’s 50-day moving average price is $184.61 and its 200 day moving average price is $147.10.

Glaukos (NYSE:GKOS – Get Free Report) last released its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.57. The company had revenue of $211.03 million for the quarter, compared to the consensus estimate of $168.04 million. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The company’s revenue was up 58.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.16) EPS. On average, equities research analysts forecast that Glaukos Corporation will post 0.50 earnings per share for the current year.

Glaukos Company Profile

(Free Report)

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.

Further Reading

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.